Kynurenic acid detection in human brain by IF
Immunohistofluorescence reveals kynurenic acid accumulation in the cytoplasm of human glial cells in human caudate-putamen. Paraffin-embedded tissue section was subjected to pH=6 antigen retrieval followed by overnight incubation with primary anti-Kynurenic acid antibody (dilution 1/250). After incubation with Alexa-555 conjugated secondary Ab, epifluorescence microscopy (100X) was used to visualize the staining.
Kynurenic acid antibodyRef: IS010
The monoclonal 4G12-A12 anti-Kynurenic acid antibody was validated for IHC and IF in human caudate putamen tissues. Competitive ELISA demonstrated the antibody to be highly affine and specific.
|Clonality||Monoclonal antibody (clone 4G12-A12)|
|Validated applications||IHC / IF
|Specie reactivity||Reacts with all species|
|References||Not yet cited to our knowledge.
Submit content and get a 10% discount!
|Shipping info :||75.00€ , 4 days|
|Product information||Protocols||References||Technical support||Reviews|
|Product name||Kynurenic acid antibody|
Kinurenic acid antibody4-Hydroxyquinoline-2-carboxylic acid antibody
|Immunogen||Conjugated kynurenic acid
|Isotype||IgG1 k chain|
|Specificity||When tested in competitive ELISA, the anti-Kynurenic antibody 4G12-A12 did not show any significant cross reactivity with Quinaldic, Xanthurenic, Anthranilic, Picolinic or Quinolinic acid conjugates
|Storage||Store at +4°C for short term (1-2 months). Aliquot and store at -20°C for long term. Avoid repeated freeze / thaw cycles.|
|Material safety datasheet
Dilute at 1:200-1:2000. Perform heat antigen retrieval (pH=6) before initiating IHC staining protocol on paraffin-embedded and frozen sections
1:100-1:1000 on paraffin-embedded and frozen sections. Before staining, perform heat antigen retrieval
Optimal working dilutions must be determined by the end-user
|Restrictions||For research use only|
Antibody not yet cited. Submit an article and get a 10% discount.
Selected articles on Kynurenic acid:
- Justinova Z, Mascia P, Wu HQ, Secci ME, Redhi GH, Panlilio LV, Scherma M, Barnes C, Parashos A, Zara T, Fratta W, Solinas M, Pistis M, Bergman J, Kangas BD, Ferré S, Tanda G, Schwarcz R, Goldberg SR. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat Neurosci. 2013 Nov;16(11):1652-61. doi: 10.1038/nn.3540. Epub 2013 Oct 13.
- Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci. 2013 Feb;34(2):136-43. doi: 10.1016/j.tips.2012.09.006. Epub 2012 Nov 1.
- Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012 Jul;13(7):465-77. doi: 10.1038/nrn3257.
- Moroni F, Cozzi A, Sili M, Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm. 2012 Feb;119(2):133-9. doi: 10.1007/s00702-011-0763-x. Epub 2012 Jan 4.
- Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012 May;38(3):426-32. doi: 10.1093/schbul/sbq086. Epub 2010 Aug 20.
- Stone TW, Forrest CM, Darlington LG. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J. 2012 Apr;279(8):1386-97. doi: 10.1111/j.1742-4658.2012.08487.x. Epub 2012 Mar 27.